Precision BioSciences

Founded in Durham, United States, Precision BioSciences, Inc. is a biotech company with a core mission to develop innovative treatments for cancer and other hard-to-treat conditions. Their vision is to leverage their proprietary ARCUS genome editing technology to create a new class of medicines that can potentially cure rare genetic diseases. ARCUS uses sequence-specific DNA-cutting enzymes to precisely edit the DNA of living cells, enabling the insertion, removal, or repair of genetic material.

Notable affiliated people include the scientists who discovered and developed the ARCUS platform. Precision BioSciences has attracted significant investment from leading biotech investors and has achieved key milestones in advancing their genome editing technology. Their impact is evident in the promising preclinical and clinical results that demonstrate the potential of ARCUS to address unmet medical needs, positioning the company as a leader in the field of genome editing and therapeutic development.